Alnylam Pharmaceuticals

ALNY

Market cap $43.9B

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the TD Cowen 46th Annual Healthcare Conference on Monday, March 2, 2026 at 9:10 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event. About Al.

Two analysts weighed in with new evaluations of the biotech. This followed last week's earnings release.

Alnylam Pharmaceuticals has declined nearly 40% from its all-time high, pressured by near-term TTR market dynamics and longer-term profitability concerns. The TTR business will likely remain "noisy" in the first half of 2026, but Amvuttra continues to gain share, and management guidance for 2026 was above expectations. Management alarmed the Street earlier this year with long-term spending guidance that was considerably higher than expected; management continues to prioritize R&D to realize the company's full long-term potential.

Alnylam tops Q4 earnings estimates but misses on sales despite 85% revenue growth, as booming Amvuttra demand fails to lift shares.

The biotech released its final set of figures for 2025. It had a mixed quarter, despite the recent success of a popular product.

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2025 Earnings Call Transcript

Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $1.25 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $0.06 per share a year ago.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2025 and reviewed recent business highlights. “2025 was a year of key accomplishments for Alnylam, highlighted by the landmark approval of AMVUTTRA for ATTR-CM in the U.S., which drove total net product revenues of nearly $3 billion, or 81% growth year-over-year, and prope.

Besides Wall Street's top-and-bottom-line estimates for Alnylam (ALNY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.